|
Introduction: Intravenous
administration of ethylene diamine tetraacetic acid (EDTA) has been used from
the beginning of the 1950's by an increasing number of physicians throughout the
world for the treatment of arteriosclerosis. In the last few years, there
has been increasing criticism of surgical intervention in this disease, since it
falls to prolong life, and is a temporary solution in treating a generalized,
chronic condition (1). In addition, surgery damages vital tissue by means of
reperfusion-released free radical bursts (2,3). Effective- ness of EDTA
chelation therapy is cumulative over many years (4,90), and the recent
association of iron in the etiology of cardiovascular disease (IO) makes the
technique worthy of complete acceptance today.
Claus Hancke, M.D. received his medical education at
the University of Copenhagen. He is in general practice and is the president of
the Danish Chelation Doctors. He is an ABCT diplomat.
Knut Flytlie,
M.D. received his medical education at the University of Gutenberg, Germany. He
is in general practice and operates a clinic for Preventive Medicine and
Chelation. He is an ABCT diplomat.
Address
correspondence to Claus Hancke, M. D.,Hovedgade 17, 1, DK- 2800-LYNGBY, Denmark.
Additional information may be obtained from ACAM. Phone number on contents page.
*In our view, the beneficial results that were
observed were far in excess of the 10-15% improvement that is usually seen in
the placebo group of a controlled study. Of 65 patients who were referred for
coronary by-pass surgery, 58 did not require it after chelation therapy. |
